Clinical experience in coronary bypass surgery for abciximab-treated patients.
Abciximab effectively inhibits platelet aggregation and, therefore, there is considerable concern regarding bleeding complications in patients who require coronary artery bypass graft (CABG) surgery while affected by the drug. This presentation reviews the available published literature regarding CABG in abciximab-treated patients, the clinical results of emergency CABG in 12 patients, and management suggestions for the abciximab-treated patient requiring emergency surgery.
Lemmer
J H
JH
Legacy Good Samaritan Hospital, Northwest Surgical Associates, Portland, Oregon, USA. jlemmerjr@aol.com
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D002315:Cardiopulmonary Bypass; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000601:surgery / Q000628:therapy*; D004638:Emergency Treatment; D006488:Hemostasis, Surgical; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019106:Postoperative Hemorrhage / Q000517:prevention & control*; D017211:Treatment Failure
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab